Suppr超能文献

[β1 选择性肾上腺素能受体阻滞剂的适应证谱]

[Indications spectrum for beta-1-selective adrenergic receptor blockers].

作者信息

Dotzer F, Gromer H

机构信息

Krankenhaus München-Perlach.

出版信息

Fortschr Med. 1993 Aug 30;111(24):382-4.

PMID:8104853
Abstract

The major indications for beta receptor blockers include, in addition to arterial hypertension, various clinical manifestations of coronary heart disease. Used as antihypertensive agents, beta receptor blockers bring about regression of myocardial hypertrophy and an improvement in diastolic ventricular function. Anti-anginal effects are utilized in the treatment of symptomatic and asymptomatic myocardial ischemia, as well as for secondary prophylaxis after acute myocardial infarction. A detailed knowledge of the subtypes of adrenoceptors--in particular beta-1 receptors in the case of the heart--led to the development of largely organ-specific antagonists. In contrast to nonspecific beta blockers, beta-1 selective substances, for example, atenolol, have only a mild, clinically non-relevant, effect on glucose and lipid metabolism.

摘要

β受体阻滞剂的主要适应证除了动脉高血压外,还包括冠心病的各种临床表现。作为抗高血压药物,β受体阻滞剂可使心肌肥厚消退,并改善心室舒张功能。其抗心绞痛作用可用于治疗有症状和无症状的心肌缺血,以及急性心肌梗死后的二级预防。对肾上腺素能受体亚型,特别是心脏中的β-1受体的详细了解,促使了大部分具有器官特异性的拮抗剂的研发。与非特异性β受体阻滞剂相比,β-1选择性药物,如阿替洛尔,对葡萄糖和脂质代谢仅有轻微的、临床上无关紧要的影响。

相似文献

2
Nitric oxide mechanisms of nebivolol.奈必洛尔的一氧化氮机制。
Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317-27. doi: 10.1177/1753944709104496. Epub 2009 May 14.
9
Are we misunderstanding beta-blockers.我们是否误解了β受体阻滞剂?
Int J Cardiol. 2007 Aug 9;120(1):10-27. doi: 10.1016/j.ijcard.2007.01.069. Epub 2007 Apr 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验